🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 482929106 (prev. 019818202 )
- Market Cap
- Mid Cap
- IPO
- 7/30/2020 · $17.00/share
- Previous Symbol
- ALVF (changed 3/12/2025)
- Previous Name
- AlloVir, Inc.
Business: AlloVir, Inc. is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases.
Notes: January 9, 2025 -- following the Special Meeting, the Board approved a reverse stock split of the Common Stock at a ratio of 1-for-23. Effective as of 4:05 p.m. Eastern Time on January 15, 2025, AlloVir filed the Reverse Stock Split Amendment and effected a 1-for-23 reverse stock split of its shares of Common Stock (the “Reverse Stock Split”). The new CUSIP number for AlloVir’s Common Stock following the Reverse Stock Split is 019818202.
Company Contact
- CEO
- Andrew Oxtoby
- CFO
- Matthew Gall
- Headquarters
- 400 Connell Drive, Suite 5500, Berkeley Heights, NJ 07922
- Phone
- 650-249-2727
- Investor Relations
- Corey Davis, LifeSci Advisors · 212-915-2577 · cdavis@lifesciadvisors.com